A webminar will be organize with the "Société de Biologie de Strasbourg" in French, on friday 19 February between 6 and 9 PM.
For more info, click here.
The Institute of Viral and Liver disease develops innovative integrative research programs addressing the next challenges in liver disease by unraveling novel therapeutic targets and biomarkers. By providing a novel understanding of liver disease biology and the discovery of novel targets and biomarkers, this program will impact the management of patients with liver disease and cancer in France, Europe and beyond. |
I- Unraveling the cell circuits of liver disease and cancer to discover novel therapeutic targets Principal Investigator: Prof. Thomas F. Baumert, MD, PhD Chronic liver disease and cancer are key challenges of public health with unsatisfactory treatment options. Key causes are chronic viral infection and metabolic disease (NASH). My laboratory focuses on unraveling the cell circuits of liver disease and cancer to discover novel therapeutic targets. Using a recently established single cell RNASeq pipeline (Aizarani, Saviano et al. Nature 2019) combined with advanced proteomics and patient-derived cell culture and animal models (Mailly et al. Nature Biotech 2015) my laboratory aims to understand the cell circuits of virus- and metabolic liver cancer (Hamdane et al. Gastroenterology 2019, Lupberger et al. Gastroenterology 2019). Furthermore, my team is exploring host cell targets to eliminate hepatitis B virus infection – a major cause of liver cancer world-wide. The understanding of disease biology on a molecular level enables us to uncover novel targets and compounds for treatment. A unique hallmark of my program is the integration of laboratory studies with patient data using advanced computational analyses. In collaboration with Biotech, Pharma and the IHU and Strasbourg University Hospitals we translate our concepts and compounds into the clinic. Associated Investigators : Dr. François Duong, PhD Dr. Atish Mukherji, PhD
II- Molecular biology of HCV virus-host interactionsPrincipal Investigator: Dr. Catherine Schuster, PhD Aiming at the identification of novel targets for preventive and therapeutic strategies against Hepatitis C virus (HCV)-induced liver disease, we focus on the characterization of virus host-interactions and the pathogenesis of HCV infection during the late steps of the HCV life cycle. We are especially interested in the relationship between HCV and cell host lipids and lipoproteins as well as the regulation of HCV IRES driven translation.
III- Signaling and virus-host interactionsPrincipal Investigator: Dr. Joachim Lupberger, PhD To uncover the signaling pathways and drivers of liver disease progression we are assessing the phospho-proteomic landscape of liver disease models. We are using cutting edge bioinformatics to identify etiology-specific and common signaling pattern and to predict regulatory circuits and drivers of liver disease progression as putative targets for chemopreventive strategies. We validate the identified pathways using liver disease animal models and conduct small molecule drug screenings targeting identified signaling pathways with potential relevance for hepatocellular carcinoma development.
IV- Molecular biology of HBV and HDV virus-host interactionsPrincipal Investigator: Dr. Eloi Verrier, PhD Our laboratory focuses on virus-host interactions in the context of hepatitis B and D virus (HBV and HDV) infections, the most aggressive forms of chronic viral hepatitis and leading causes of hepatocellular carcinoma worldwide. To date, no treatment allows viral cure. Our key focus is to understand the viral life cycle of HDV and uncover hepatocyte host factors mediating HDV infection as novel therapeutic targets for cure. In collaboration with national and international leading research groups, we are applying novel model systems and cutting-edge functional genomics for drug and target discovery. The discovery of new therapeutic agents targeting these candidate host factors constitutes a major step towards the development of novel treatments for viral cure.
V- SARS-CoV-2 coronavirus-host interactions and therapeutic targetsPrincipal Investigator: Prof. Thomas F. Baumert, MD, PhD The novel Coronavirus SARS-CoV-2 that emerged in China in December 2019 and is continuing to spread all over the world constitutes a major public health emergency. With currently almost 130.000 people infected and close to 5000 deceased from the Covid-19 disease the search for factors involved in virus spread and replication is paramount to develop tools to fight the ongoing pandemic. Using our internationally recognized expertise to discover host factors as targets for antiviral therapy (Lupberger et al, Nat Med 2011; Zona et al, Cell Host Microbe 2013; Mailly, Nat Biotechnol 2015; Verrier et al, Hepatology 2016; Colpitts et al, Gut 2018, Verrier ER, Gut 2020; reviewed in Crouchet et al, Therap Adv Gastroenterol 2018) we have established the expertise and model systems to contribute to the global effort to find novel compounds to fight SARS-CoV-2 infection. Using established coronavirus model systems (Letko et al, Nat Microbiol 2020, Hoffmann et al, Cell 2020) we will discover host factors for the coronavirus life cycle focusing on virus cell entry and replication. Specifically, we will assess the antiviral activity of compounds targeting common host factors of HCV and coronaviruses. Collectively, we anticipate that our program will uncover novel strategies and compounds for antiviral therapy for urgently needed control and cure of coronavirus infection. VI- Relevance and Course of care Principal Investigator : Prof. Patrick Pessaux , MD, PhD
|
National French contracts
ANRS, ANR, LabEx HepSYS, IdEx, Fondation BNP-Paribas, CONECTUS, Fondation Recherche Médicale, Insitut National du Cancer, La Ligue Contre le Cancer, Région Alsace, Fondation ARC Pour La Recherche Sur Le Cancer, Fondation Université de Strasbourg, Institut Roche, Euromedex
International Contracts
European Union, Fond Européen de Développement Régional (FEDER), Interreg IV Rhin Supérieur (Hepato-Regio-Net), European Research Council, Infect-ERA, Horizon 2020, Foundation Else-Kröner-Fresenius, German Liver Foundation, Inserm EAL University of Freibourg, National Institute Of Allergy And Infectious Diseases of the National Institutes of Health
A webminar will be organize with the "Société de Biologie de Strasbourg" in French, on friday 19 February between 6 and 9 PM.
For more info, click here.
Congratulation to the Pr Thomas Baumert for receiving with honor the "Memain-Pelletier" prize from "Académie des Sceinces" for his work on virus -hoste interactions in liver disease and cancer.
You can find more details cliking here (in French)
Unit U1110 is welcoming a new research project "Relevance and course of care" directed by the Prof. Patrick Pessaux
Dr Atish Mukherji published a new article in "Fellow 2020" : "Investigating the role of the cicadian clock and the 3-dimensional chromatin architecture in the development of hepatitis C virus (HCV) - induced liver disease. Find the article here
Congrats to Dr. Antonio Saviano for receiving the 2020 SCHWEITZER PhD prize from the “ Chapitre de Saint Thomas" for his work carried out in our institute on the single cell liver atlas.
The ceremony will take place at "église Saint Thomas" the 4th November in Stasbourg.
June 2020: In order to strengthen our team, we are looking to recruit a technician in biology with expertise in cell culture to participate in an innovative research project on the circadian clock and liver diseases.
June 2020 : Computational analyst/bioinformatics position in drug and target discovery for human liver disease and cancer using single cell RNASeq
We are seeking PhD students. We are interested in hearing from you! Our post-graduate training program is designed to guarantee your development into a world class research scientist.
June 2020: Post-doctoral positions to develop antiviral therapies targeting the new coronavirus cell entry for COVID-19 control and cure
The Inserm Unit U1110, Strasbourg, France is inviting applications from junior group leaders with an excellent track record and a research interest in the study of virus-host interactions.
Charlotte Bach Tech Inserm Tel. +33 (0)3.68.85.37.27 cbach@unistra.fr |
Dr. Laurent Mailly IR Unistra Animal models platfrom responsible Tel. +(0)3.68.85.37.91 laurent.mailly@unistra.fr |
Dr. Simonetta Bandiera Postdoc Tel. +33 (0)3.68.85.37.27 sbandiera@unistra.fr |
Marine Oudot Tech CDD Unistra Tel. +(0)3.68.85.37.13 laurent.mailly@unistra.fr |
Prof. Thomas Baumert Head Inserm U1110 Group leader Tel. +33 (0)3.68.85.37.03 Thomas.Baumert@unistra.fr Contact Prof. Baumert's assistant |
Marie Parnot Tech Inserm Tel. +33 (0)3.68.85.37.07 m.parnot@unistra.fr |
Nicolas Brignon Tech Unistra Tel. +33 (0)3.68.85.37.30 nicolas.brignon@unistra.fr |
Richard Pidl Animal care Tel. +33 (0)3.68.85.37.30 Richard.Pidl@unistra.fr |
Dr. Che Colpitts Postdoc Tel. +33 (0)3.68.85.37.38 colpitts@unistra.fr |
Andres Roca PhD student Tel. +33 (0)3.68.85.37.38 andres.roca-suarez@etu.unistra.fr |
Catherine Corbel Prof. Baumert's personal assistant Tel. +33 (0)3.68.85.37.03 catherine.corbel@unistra.fr |
Dr. Eric Robinet Group leader Tél. +33 (0)3.88.11.91.73 and +33 (0)3.68.85.37.91 eric.robinet@ihu-strasbourg.eu |
Emilie Crouchet PhD student Tel. +33 (0)3.68.85.37.07 emilie.crouchet@etu.unistra.fr |
Dr. Catherine Schuster Deputy Director Inserm U1110 Group leader Tél. +33 (0)3.68.85.37.41 catherine.schuster@unistra.fr |
Sarah Durand Tech Unistra Tel. +33 (0)3.68.85.37.27 s.durand@unistra.fr |
Sigis Sliwinski IT support and logistics Tel. +33 (0)3.68.85.37.13 Sigismond.Sliwinski@unistra.fr |
Dr. Houssein El Saghire Postdoc Tel. +33 (0)3.68.85.37.38 elsaghire@unistra.fr |
Dr. Christine Thumann IR Inserm BSL3 platform responsbile Tel. +33 (0)3.68.85.37.38 christine.thumann@unistra.fr |
Dr. Catherine Fauvelle Postdoc Tel. +33 (0)3.68.85.37.38 fauvelle@unistra.fr |
Nicolaas Van Renne PhD student Tél. +33 (0)3.68.85.37.38 vanrenne@unistra.fr |
Jérémy Grasser Maintenance Tel. +33 (0)3.68.85.37.46 j.grasser@unistra.fr |
Dr. Eloi Verrier Postdoc Tel. +33 (0)3.68.85.37.38 e.verrier@unistra.fr |
Dr. Nourdine Hamdane Postdoc Tel. +33 (0)3.68.85.37.38 anhamdane@unistra.fr |
Patricia Wechsler Glassware and autoclaving Tel. +33 (0)3.68.85.37.13 patricia.wechsler@unistra.fr |
Emilie Heuillard Tech CDD IHU Tel. +33 (0)3.68.85.37.91 emilie.heuillard@ihu-strasbourg.eu |
SeungAe Yim PhD student Tel. +(0)3.68.85.37.07 seungae.yim@etu.unistra.fr |
Laura Heydmann AI Unistra Tel. +33 (0)3.68.85.37.27 heydmann@unistra.fr |
Dr. Mirjam Zeisel Goup leader Tel. +33 (0)3.68.85.37.09 mirjam.zeisel@unistra.fr |
Dr. Olga Koutsopoulos IR CDD Inserm Project manager Tel. +33 (0)3.68.85.37.38 koutsopoulos@unistra.fr |
Anne Zeter Financial officer and grant manager Tel. +33 (0)3.68.85.37.02 anne.zeter@unistra.fr |
Dominique Lecestre Logistics and equipment Tel. +33 (0)3.68.85.37.08 lecestre@unistra.fr |
|
Dr. Joachim Lupberger Staff scientist Tel. +33 (0)3 68 85 37 15 joachim.lupberger@unistra.fr |
Le site www.u1110.inserm.fr est une publication éditée par l'unité de recherche Inserm 1110,
Unité Inserm UMR 1110
Institut de Recherche sur les Maladies Virales et Hépatiques
3 rue Koeberlé
67000 Strasbourg
Téléphone : 03 68 85 37 03
Directeur de la publication : Thomas Baumert, directeur de l'unité 1110.
Webmestre : Olga Koutsopoulos (contacter le webmestre)
Hébergement : agence Tiz
L'utilisation du site est réservée à un usage personnel. L'accès au site peut être interrompu à tout moment, sans préavis, notamment en cas de force majeure, de maintenance ou si son éditeur décide de suspendre ou d'arrêter la fourniture de ce service.
L'éditeur s'efforce d'assurer au mieux de ses possibilités, l'exactitude et la mise à jour des informations diffusées, au moment de leur mise en ligne sur le site. Cependant, il ne garantit en aucune façon l'exactitude, la précision ou l'exhaustivité des informations mises à disposition. Les informations présentes sur le site sont non-contractuelles et peuvent être modifiées à tout moment.
Le site est régi par la loi française. Les utilisateurs étrangers acceptent formellement l'application de la loi française en visitant ce site et en utilisant tout ou partie des fonctionnalités du site.
Propriété intellectuelle
Les contenus qui apparaissent ou sont disponibles sur le site sont protégés par le droit de la propriété intellectuelle et sont la propriété exclusive de l'éditeur. A ce titre, vous vous engagez à ne pas copier, traduire, reproduire, vendre, publier, exploiter et diffuser des contenus du site protégés par le droit de la propriété intellectuelle, sans autorisation préalable et écrite de l'éditeur.
Vie privée
L'éditeur s'engage à ne pas divulguer à des tiers les informations que l'internaute lui communique. Celles-ci sont confidentielles et ne seront utilisées que pour les besoins du service.Le site répond à la réglementation relative à l'informatique, aux fichiers et aux libertés telle que définie par la loi n°78-17, modifiée. L'internaute dispose, pour ce qui concerne ses données personnelles collectées lors de sa visite sur le site, d'un droit d'accès, de modification, de rectification et de suppression des données conformément à la loi française. Ces droits peuvent être exercés auprès de l'éditeur : unité 1110 dot l'adresse figure plus haut
Liens
Le site peut contenir des liens vers des sites de partenaires ou de tiers. L'Inserm ne disposant d'aucun moyen pour contrôler ces sites n'offre aucune garantie quant au respect par ces sites des lois et règlement en vigueur.
Alerte démarchage
L'éditeur ne vend aucun emplacement publicitaire dans sa publication. Toute démarche en ce sens, est faite en fraude des droits de l'éditeur.
Site réalisé par :
104, rue de Hochfelden
67200 STRASBOURG
Tél : 03 67 10 18 50
www.tiz.fr
En collaboration avec la Délégation régionale Grand-Est de l'Inserm et l'unité Inserm 1110.
Crédits photos :
Inserm/P. Delapierre, O. Koutsopoulos, M. Zeisel, C. Heinrich, unité Inserm 1110
Contact : Banque d'images de l'Inserm : www.serimedis.inserm.fr